Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics (Nasdaq: CYTK) granted inducement equity awards on March 13, 2026 to five new employees hired in February–March 2026: 8,628 stock options and 5,719 RSUs.

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) granted inducement equity awards on March 13, 2026 to five new employees hired in February–March 2026: 8,628 stock options and 5,719 RSUs. Options carry a $60.06 exercise price and 10-year term; RSUs vest over three years per schedule. Awards follow Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2004 Equity Incentive Plan and award agreements.

Argus Mar 19 session

+1.22% close to close Open Argus

Details

News Market Reaction – CYTK

On Mar 19, the first trading day after this news, CYTK closed 1.22% above the previous close.

Data tracked by StockTitan Argus for the Mar 19 session.

Market Context

This announcement details standard hiring-related equity compensation: stock options on 8,628 shares...

Analysis

This announcement details standard hiring-related equity compensation: stock options on 8,628 shares and 5,719 RSUs granted to five new employees, with RSUs vesting 40/40/20 over three years and options vesting over four years at an exercise price of $60.06. These awards are made under the company’s Amended and Restated 2004 Equity Incentive Plan and Nasdaq Listing Rule 5635(c)(4). Investors may track how such grants fit alongside recent insider Form 4 activity and ongoing clinical and commercial milestones.

Key Figures

Current share price: $62.13 Stock options granted: 8,628 options RSUs granted: 5,719 RSUs +5 more

Current share price

$62.13

Pre-news market context

Stock options granted

8,628 options

Inducement grants to new employees on March 13, 2026

RSUs granted

5,719 RSUs

Inducement grants to new employees on March 13, 2026

Employees receiving awards

5 employees

New hires in February and March 2026

RSU vesting schedule

40%/40%/20% over 3 years

Annual anniversaries of grant date, subject to continued service

Option vesting period

4 years

1/4 after 1 year, then monthly over 36 months

Option exercise price

$60.06 per share

Equal to closing price on March 13, 2026

Option term

10 years

Contractual life of inducement stock options

Historical Context

5 past events · Latest: Mar 16

5 events

1. Mar 16

   Clinical data update

   24h Move

   +0.9%

   ACC 2026 presentations highlighting MYQORZO data in oHCM patients.

2. Mar 02

   Investor conferences

   24h Move

   -1.2%

   Participation in multiple March investor events and webcast availability.

3. Feb 24

   Earnings and update

   24h Move

   -10.3%

   Q4 2025 results, MYQORZO approvals, cash position and 2026 guidance.

4. Feb 17

   Regulatory approval

   24h Move

   +0.5%

   European Commission approval of MYQORZO for symptomatic oHCM.

5. Feb 12

   Earnings date set

   24h Move

   +1.9%

   Announcement of Q4 2025 earnings release date and conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, stock options, exercise price, Nasdaq Listing Rule 5635(c)(4), +1 more

5 terms

restricted stock units financial

"and 5,719 restricted stock units (RSUs) that will be settled in shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options financial

"it granted stock options to purchase an aggregate of 8,628 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The stock options that were granted are subject to an exercise price of $60.06"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity incentive plan financial

"the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 13, 2026 it granted stock options to purchase an aggregate of 8,628 shares of common stock and 5,719 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in February and March 2026 as a material inducement to their employment.

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of $60.06 per share, which is equal to the closing price of the Company’s common stock on March 13, 2026 and will vest over 4 years, with 1/4^th of the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48^th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO™ (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did Cytokinetics (CYTK) announce on March 18, 2026?

Cytokinetics granted inducement awards of 8,628 stock options and 5,719 RSUs to five new hires. According to the company, options were priced at $60.06 per share and RSUs vest over three years under the 2004 Equity Incentive Plan.

When do the RSUs granted by Cytokinetics (CYTK) on March 13, 2026 vest?

The RSUs vest over three years with 40% at year one, 40% at year two, and 20% at year three. According to the company, vesting is subject to each employee's continued service with Cytokinetics.

What are the vesting terms and exercise price for the CYTK stock options granted March 13, 2026?

Options vest over four years with 25% at the one-year anniversary and monthly vesting thereafter; exercise price is $60.06 per share. According to the company, each option has a 10-year term and is subject to award agreement terms.

Why did Cytokinetics (CYTK) use inducement grants for the new hires in March 2026?

The grants were issued as material inducements to employment in line with Nasdaq Listing Rule 5635(c)(4). According to the company, the awards were provided to recruit employees who commenced employment in February and March 2026.

How are the March 13, 2026 CYTK awards governed and where do they settle?

The awards are governed by the Amended and Restated 2004 Equity Incentive Plan and applicable award agreements and RSUs will settle in shares of common stock upon vesting. According to the company, standard plan terms and award agreements apply.